UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042 ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

UroGen has issued $4m in ordinary shares to IconOVir. Credit: MacroEcon/Shutterstock. UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic ...

Replimune has established itself as a leader in the field of oncolytic immunotherapy, focusing on developing novel treatments for various cancers. The company's wholly-owned pipeline and advanced ...

(NASDAQ: URGN), a biotech company focused on urothelial and specialty cancers trading at $10.82 per share, has announced the acquisition of a novel oncolytic virus, ICVB-1042, from IconOVir Bio ...

“The acquisition of ICVB-1042, a next-generation investigational oncolytic virus, marks a significant milestone in our plan to develop novel, locally administered therapies for bladder cancer ...

Despite their potential, oncolytic viruses encounter several challenges as standalone therapies. Consequently, the combination of oncolytic viruses with other therapeutic modalities has emerged as a ...

Biotherapeutics announced that Northwestern University/Northwestern Memorial Hospital is starting recruitment for the CLD-101 ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...